SCHEMBL5954427

SCHEMBL5954427

O=C1CN(c2ccc(OCc3ccccc3)cc2)C(=S)N1c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
POLB P06746 2/20 0.50
NR1H4 Q96RI1 1/20 0.48
RAB9A P51151 3/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
NPC1 O15118 2/20 0.47
MMP13 P45452 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
GRM5 P41594 1/20 0.45
PKM P14618 1/20 0.44
GSTP1 P09211 1/20 0.43
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
PTGS1 P23219 1/20 0.43
SLC6A2 P23975 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6168242 0.89 MEN1 (0.57) MEN1KMT2APOLBNR1H4RAB9A
SCHEMBL5955047 0.82 KMT2A (0.56) MEN1KMT2APOLBRAB9AL3MBTL1
SCHEMBL5955275 0.82 KMT2A (0.56) MEN1KMT2APOLBRAB9AL3MBTL1
SCHEMBL5955129 0.82 PLCG1 (0.55) MEN1KMT2APOLBRAB9ANPC1
SCHEMBL1685398 0.81 KMT2A (0.56) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL5954399 0.80 SMN1; SMN2 (0.54) MEN1KMT2APOLBRAB9ANPC1
SCHEMBL5955353 0.79 SIRT1 (0.52) NR1H4RAB9AL3MBTL1NPC1MMP13
SCHEMBL5697582 0.76 MMP13 (0.54) RAB9AL3MBTL1NPC1MMP13SMN1; SMN2
SCHEMBL11072116 0.76 KMT2A (0.49) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL11065342 0.76 HTT (0.53) MEN1KMT2ARAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060025589-A1 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes LABORATOIRES FOURNIER S.A. (FR) 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025589-A1 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes LIPC, CYP4F2, SLC5A2 MEN1 3372/4885KMT2A 1991/4885POLB 4612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.